Cargando…

Inducible Tertiary Lymphoid Structures: Promise and Challenges for Translating a New Class of Immunotherapy

Tertiary lymphoid structures (TLS) are ectopically formed aggregates of organized lymphocytes and antigen-presenting cells that occur in solid tissues as part of a chronic inflammation response. Sharing structural and functional characteristics with conventional secondary lymphoid organs (SLO) inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Aoyama, Shota, Nakagawa, Ryosuke, Mulé, James J., Mailloux, Adam W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160316/
https://www.ncbi.nlm.nih.gov/pubmed/34054863
http://dx.doi.org/10.3389/fimmu.2021.675538
_version_ 1783700258051588096
author Aoyama, Shota
Nakagawa, Ryosuke
Mulé, James J.
Mailloux, Adam W.
author_facet Aoyama, Shota
Nakagawa, Ryosuke
Mulé, James J.
Mailloux, Adam W.
author_sort Aoyama, Shota
collection PubMed
description Tertiary lymphoid structures (TLS) are ectopically formed aggregates of organized lymphocytes and antigen-presenting cells that occur in solid tissues as part of a chronic inflammation response. Sharing structural and functional characteristics with conventional secondary lymphoid organs (SLO) including discrete T cell zones, B cell zones, marginal zones with antigen presenting cells, reticular stromal networks, and high endothelial venues (HEV), TLS are prominent centers of antigen presentation and adaptive immune activation within the periphery. TLS share many signaling axes and leukocyte recruitment schemes with SLO regarding their formation and function. In cancer, their presence confers positive prognostic value across a wide spectrum of indications, spurring interest in their artificial induction as either a new form of immunotherapy, or as a means to augment other cell or immunotherapies. Here, we review approaches for inducible (iTLS) that utilize chemokines, inflammatory factors, or cellular analogues vital to TLS formation and that often mirror conventional SLO organogenesis. This review also addresses biomaterials that have been or might be suitable for iTLS, and discusses remaining challenges facing iTLS manufacturing approaches for clinical translation.
format Online
Article
Text
id pubmed-8160316
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81603162021-05-29 Inducible Tertiary Lymphoid Structures: Promise and Challenges for Translating a New Class of Immunotherapy Aoyama, Shota Nakagawa, Ryosuke Mulé, James J. Mailloux, Adam W. Front Immunol Immunology Tertiary lymphoid structures (TLS) are ectopically formed aggregates of organized lymphocytes and antigen-presenting cells that occur in solid tissues as part of a chronic inflammation response. Sharing structural and functional characteristics with conventional secondary lymphoid organs (SLO) including discrete T cell zones, B cell zones, marginal zones with antigen presenting cells, reticular stromal networks, and high endothelial venues (HEV), TLS are prominent centers of antigen presentation and adaptive immune activation within the periphery. TLS share many signaling axes and leukocyte recruitment schemes with SLO regarding their formation and function. In cancer, their presence confers positive prognostic value across a wide spectrum of indications, spurring interest in their artificial induction as either a new form of immunotherapy, or as a means to augment other cell or immunotherapies. Here, we review approaches for inducible (iTLS) that utilize chemokines, inflammatory factors, or cellular analogues vital to TLS formation and that often mirror conventional SLO organogenesis. This review also addresses biomaterials that have been or might be suitable for iTLS, and discusses remaining challenges facing iTLS manufacturing approaches for clinical translation. Frontiers Media S.A. 2021-05-14 /pmc/articles/PMC8160316/ /pubmed/34054863 http://dx.doi.org/10.3389/fimmu.2021.675538 Text en Copyright © 2021 Aoyama, Nakagawa, Mulé and Mailloux https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Aoyama, Shota
Nakagawa, Ryosuke
Mulé, James J.
Mailloux, Adam W.
Inducible Tertiary Lymphoid Structures: Promise and Challenges for Translating a New Class of Immunotherapy
title Inducible Tertiary Lymphoid Structures: Promise and Challenges for Translating a New Class of Immunotherapy
title_full Inducible Tertiary Lymphoid Structures: Promise and Challenges for Translating a New Class of Immunotherapy
title_fullStr Inducible Tertiary Lymphoid Structures: Promise and Challenges for Translating a New Class of Immunotherapy
title_full_unstemmed Inducible Tertiary Lymphoid Structures: Promise and Challenges for Translating a New Class of Immunotherapy
title_short Inducible Tertiary Lymphoid Structures: Promise and Challenges for Translating a New Class of Immunotherapy
title_sort inducible tertiary lymphoid structures: promise and challenges for translating a new class of immunotherapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160316/
https://www.ncbi.nlm.nih.gov/pubmed/34054863
http://dx.doi.org/10.3389/fimmu.2021.675538
work_keys_str_mv AT aoyamashota inducibletertiarylymphoidstructurespromiseandchallengesfortranslatinganewclassofimmunotherapy
AT nakagawaryosuke inducibletertiarylymphoidstructurespromiseandchallengesfortranslatinganewclassofimmunotherapy
AT mulejamesj inducibletertiarylymphoidstructurespromiseandchallengesfortranslatinganewclassofimmunotherapy
AT maillouxadamw inducibletertiarylymphoidstructurespromiseandchallengesfortranslatinganewclassofimmunotherapy